Related Experiment Videos

Pharmacokinetics of hydrochlorothiazide in patients with congestive heart failure

Insights

Hydrochlorothiazide (HCT) shows reduced gastrointestinal uptake and altered pharmacokinetics in patients with cardiac failure. Its plasma half-life correlates with creatinine clearance, indicating significant changes in drug handling during heart failure.

Area of Science:

  • Pharmacology
  • Cardiology
  • Nephrology

Background:

  • Cardiac failure significantly impacts drug pharmacokinetics.
  • Understanding drug behavior in heart failure is crucial for effective treatment.

Purpose of the Study:

  • To investigate the pharmacokinetics of hydrochlorothiazide (HCT) in patients with cardiac failure.
  • To assess the impact of cardiac failure on HCT absorption, distribution, and elimination.

Main Methods:

  • Oral administration of hydrochlorothiazide (50-75 mg) to seven cardiac failure patients.
  • Quantification of plasma and urinary HCT levels using gas-liquid chromatography (GLC).
  • Correlation analysis between HCT plasma half-life and endogenous creatinine clearance.

Main Results:

  • Reduced gastrointestinal uptake of HCT, approximately halved compared to healthy controls.
  • Plasma half-life of HCT demonstrated a correlation with endogenous creatinine clearance.
  • Significant alterations in HCT pharmacokinetics were observed in patients with cardiac failure.

Conclusions:

  • Cardiac failure markedly alters the pharmacokinetic profile of hydrochlorothiazide.
  • Reduced absorption and changes in elimination necessitate careful consideration of HCT dosing in heart failure patients.
  • Creatinine clearance is a relevant factor influencing HCT disposition in this population.

Related Concept Videos